Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $305M Series F for AI peptides targeting undruggable cancer proteins (Jan 2026).
Parabilis Medicines is a clinical-stage biotechnology company applying AI to the design of peptide-based therapeutics targeting proteins previously considered undruggable, with a primary focus on oncology. The company was founded on the insight that AI-optimized peptides — short chains of amino acids — can be engineered to reach and modulate intracellular protein targets that small molecules and biologics cannot access. Parabilis uses proprietary computational platforms to design, screen, and optimize peptide candidates with improved cell permeability, stability, and target selectivity.\n\nThe company's pipeline is centered on cancer proteins that drive tumor growth but lack conventional binding pockets for small molecule inhibition. Parabilis's AI-designed peptides are engineered to penetrate cancer cells and disrupt these oncogenic interactions, potentially unlocking entirely new therapeutic options for patients with tumors driven by these targets. The approach also has potential applications in other diseases where intracellular protein-protein interactions are central to pathology.\n\nParabilis raised $305M in a Series F round in January 2026, one of the largest biotech fundraises of that period. The financing was designed to advance its lead programs through clinical development and expand its pipeline of AI-designed peptide candidates. With over $300M in fresh capital, Parabilis is one of the most heavily funded companies in the emerging AI peptide therapeutics space, positioning it to compete with both traditional peptide drug developers and newer AI-native biotech platforms.
Indoor vertical farming company using AI-optimized growing systems. San Francisco, CA. Raised $940M+ including $400M from SoftBank. Partners with Walmart for US farms.
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has raised over $940 million from investors including SoftBank Vision Fund, which invested $200 million in 2017, and has positioned itself as the technology leader in data-driven indoor agriculture.\n\nPlenty's farms use precisely controlled light, temperature, humidity, and nutrient conditions to grow crops that are free from pesticides, use 99% less land, and consume significantly less water than conventional field agriculture. The company's AI systems continuously optimize growing conditions based on sensor data, learning to improve yields and quality across crops and growing cycles.\n\nIn 2022, Plenty announced a landmark partnership with Walmart to supply leafy greens from a new large-scale facility in Compton, California. This partnership provided both a major commercial anchor and significant additional funding from Walmart, validating Plenty's technology and business model at scale. The company also operates a dedicated strawberry R&D partnership with Driscoll's, the world's largest berry company, demonstrating the platform's potential beyond leafy greens.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.